|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.580 CNY | +5.08% |
|
+6.29% | +8.98% |
| 01-06 | Jointown Subsidiary Gets China Approval for Anesthetic | MT |
| 12-29 | Jointown Pharmaceutical Gets Completion Ruling for Subsidiary's Reorganization | MT |
| Capitalization | 27.82B 4B 3.4B 3.15B 2.94B 5.49B 367B 5.82B 36B 14.29B 173B 14.98B 14.68B 631B | P/E ratio 2025 * |
10.6x | P/E ratio 2026 * | 10.4x |
|---|---|---|---|---|---|
| Enterprise value | 24.02B 3.45B 2.93B 2.72B 2.54B 4.74B 317B 5.02B 31.08B 12.34B 150B 12.94B 12.67B 544B | EV / Sales 2025 * |
0.15x | EV / Sales 2026 * | 0.13x |
| Free-Float |
41.34% | Yield 2025 * |
4% | Yield 2026 * | 3.95% |
| 1 day | +5.08% | ||
| 1 week | +6.29% | ||
| Current month | +8.98% | ||
| 1 month | +9.20% | ||
| 3 months | +11.38% | ||
| 6 months | +3.14% | ||
| Current year | +8.98% |
| 1 week | 5.2 |  | 5.84 |
| 1 month | 5.05 | | 5.84 |
| Current year | 5.13 | | 5.84 |
| 1 year | 4.57 | | 5.84 |
| 3 years | 4.35 | | 6.94 |
| 5 years | 3.97 | | 7.25 |
| 10 years | 3.97 | | 8.99 |
| Manager | Title | Age | Since |
|---|---|---|---|
Wei He
CEO | Chief Executive Officer | 40 | 2022-04-22 |
Xi Zhang
IRC | Investor Relations Contact | - | 2022-04-22 |
Zhi Feng Liu
IRC | Investor Relations Contact | 43 | 2009-01-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Zhao Nian Liu
BRD | Director/Board Member | 66 | 2008-11-15 |
Deng Pan Liu
BRD | Director/Board Member | 48 | 2020-11-04 |
Yi Hua Gong
BRD | Director/Board Member | 48 | 2012-06-30 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +5.08% | +6.29% | +14.11% | +9.92% | 4B | |
| +0.39% | -2.41% | +37.35% | +118.71% | 101B | |
| +0.70% | -1.94% | +61.12% | +176.01% | 49.5B | |
| +1.32% | +5.52% | - | - | 24.18B | |
| -0.24% | -2.59% | +9.44% | -22.96% | 9.47B | |
| +0.98% | +0.69% | -11.09% | -6.72% | 8.41B | |
| +0.97% | +0.87% | +3.48% | +7.66% | 8.32B | |
| +2.71% | -2.06% | +11.45% | +77.07% | 6.92B | |
| -0.67% | -1.37% | +21.72% | +30.75% | 6.13B | |
| Average | +1.25% | +0.30% | +18.45% | +48.80% | 24.24B | |
| Weighted average by Cap. | +0.71% | -1.33% | +36.60% | +109.71% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 162B 23.24B 19.77B 18.32B 17.12B 31.92B 2,135B 33.83B 209B 83.13B 1,008B 87.15B 85.37B 3,668B | 170B 24.47B 20.81B 19.29B 18.02B 33.6B 2,248B 35.61B 220B 87.51B 1,061B 91.74B 89.86B 3,861B |
| Net income | 2.65B 381M 324M 300M 280M 523M 34.97B 554M 3.43B 1.36B 16.51B 1.43B 1.4B 60.05B | 2.7B 388M 330M 306M 286M 533M 35.63B 565M 3.49B 1.39B 16.82B 1.45B 1.42B 61.2B |
| Net Debt | -3.8B -546M -464M -430M -402M -750M -50.16B -795M -4.92B -1.95B -23.68B -2.05B -2.01B -86.15B | -5.82B -835M -711M -659M -615M -1.15B -76.75B -1.22B -7.53B -2.99B -36.24B -3.13B -3.07B -132B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-01-23 | 5.580 ¥ | +5.08% | 234,331,400 |
| 26-01-22 | 5.310 ¥ | +1.14% | 38,869,820 |
| 26-01-21 | 5.250 ¥ | -0.57% | 31,847,170 |
| 26-01-20 | 5.280 ¥ | +0.38% | 48,283,850 |
| 26-01-19 | 5.260 ¥ | +0.19% | 45,042,840 |
End-of-day quote Shanghai S.E., January 22, 2026
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 600998 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition